Further evidence of this is observed in the heightened expression levels of RUNX1 and its downstream target, REXO2, in isocitrate dehydrogenase wild-type low-grade gliomas, indicative of a poor prognosis 49. The gene discussed is REXO2; the disease is central nervous system cancer.